Cargando…
A commentary on “PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron”
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349749/ https://www.ncbi.nlm.nih.gov/pubmed/35942238 http://dx.doi.org/10.1002/ctd2.87 |
| _version_ | 1784762148112564224 |
|---|---|
| author | Muthu, Sakthijothi Venkatesh, Sundararajan |
| author_facet | Muthu, Sakthijothi Venkatesh, Sundararajan |
| author_sort | Muthu, Sakthijothi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9349749 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93497492022-08-04 A commentary on “PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron” Muthu, Sakthijothi Venkatesh, Sundararajan Clin Transl Discov Commentary John Wiley and Sons Inc. 2022-06-10 2022-06 /pmc/articles/PMC9349749/ /pubmed/35942238 http://dx.doi.org/10.1002/ctd2.87 Text en © 2022 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Commentary Muthu, Sakthijothi Venkatesh, Sundararajan A commentary on “PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron” |
| title | A commentary on “PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron” |
| title_full | A commentary on “PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron” |
| title_fullStr | A commentary on “PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron” |
| title_full_unstemmed | A commentary on “PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron” |
| title_short | A commentary on “PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron” |
| title_sort | commentary on “pi3k‐α/mtor/brd4 inhibitor alone or in combination with other anti‐virals blocks replication of sars‐cov‐2 and its variants of concern including delta and omicron” |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349749/ https://www.ncbi.nlm.nih.gov/pubmed/35942238 http://dx.doi.org/10.1002/ctd2.87 |
| work_keys_str_mv | AT muthusakthijothi acommentaryonpi3kamtorbrd4inhibitoraloneorincombinationwithotherantiviralsblocksreplicationofsarscov2anditsvariantsofconcernincludingdeltaandomicron AT venkateshsundararajan acommentaryonpi3kamtorbrd4inhibitoraloneorincombinationwithotherantiviralsblocksreplicationofsarscov2anditsvariantsofconcernincludingdeltaandomicron AT muthusakthijothi commentaryonpi3kamtorbrd4inhibitoraloneorincombinationwithotherantiviralsblocksreplicationofsarscov2anditsvariantsofconcernincludingdeltaandomicron AT venkateshsundararajan commentaryonpi3kamtorbrd4inhibitoraloneorincombinationwithotherantiviralsblocksreplicationofsarscov2anditsvariantsofconcernincludingdeltaandomicron |